15th International Conference on Digestive Disorders and Gastroenterology July 11-12, 2018 Sydney, Australia

Biography:

Higinio T Mappala is a Cum Laude Graduate of University of Santo Tomas, College of Medicine, Manila, Philippines, A Board-certified Internist, Gastroenterologist, Endoscopist, Clinical Nutritionist and Clinical Toxicologist; has served as a University Professor and Dean of 2 Medical Schools; a highly-regarded Researcher, with more than 50 scientific papers, and more than 20 publications. He is a former Board Director of the Philippine Societies of Gastroenterology and Digestive Endoscopy, an online Research rater of McMaster, Canada and Online Dynamed Research peer reviewer and a Young Investigator’s Awardee at the World Congress and Asia-Pacific Congress of Gastroenterology. He has attended the 3-level training courses on Leadership and Management by the World Gastroenterology Organization held in Florida, USA, Dubrovnic, Croatia and Porto, Portugal. He is a focused lecturer on NAFLD in local and international conventions.

Abstract:

Non-alcoholic fatty liver disease (NAFLD) is one of the most common forms of chronic liver disease which may progress to non-alcoholic steatohepatitis (NASH). Currently there are no therapeutic strategies for such disease. Only lifestyle modification through diet and exercise were proven to afford some benefit in patients with NAFLD. No pharmacologic agents have so far been approved for the treatment of NAFLD or NASH. Therefore, most clinical efforts have been directed at treating the components of metabolic syndrome, namely obesity, diabetes, hypertension and dyslipidemias. Other interventions are directed at specific pathways potentially involved in the pathogenesis of NAFLD, such as insulin resistance, oxidative stress, pro-inflammatory cytokines, apoptosis, bacterial overgrowth and angiotensin pathway. This lecture aims to show the potential of bile acids as a promising therapeutic option for NAFLD. This is a 10-year systematic review of the effects of bile acids on non-alcoholic fatty liver disease (NAFLD). Bile acids may yet prove to be an effective targeted treatment for non-alcoholic fatty liver disease.